



## *Curriculum Vitae*

### **Jason Byron Thompson, MD**

Alabama Clinical Therapeutics, LLC  
52 Medical Park East Drive  
Suite 203  
Birmingham, Alabama 35235

Telephone: 205.833.2228 Fax: 205.833.6225 Email: [jason.thompson@actstudy.net](mailto:jason.thompson@actstudy.net)

#### **Additional Offices:**

Birmingham Heart Clinic, PC  
100 Pilot Medical Drive, Suite 300  
Birmingham, Alabama 35235

#### **Education:**

2005-2008	Fellowship, Cardiology John Hopkins Hospital Baltimore, MD
2004-2005	Chief Medical Resident University of Alabama at Birmingham Birmingham, AL
2001-2004	Residency, Cardiology University of Alabama at Birmingham Birmingham, AL
1997-2001	Doctor of Medicine University of Alabama at Birmingham Birmingham, AL
1994-2000	Doctor of Philosophy, Chemical Engineering Auburn University Auburn, AL
06/1998-08/1998	Anesthesia Extern University Hospital Birmingham, AL
1989-1993	Bachelor of Science, Chemical Engineering Auburn University Auburn, AL

**Training and Work Experience:**

10/2020 - Present	Investigator, Alabama Clinical Therapeutics, LLC Birmingham, Alabama
2008 – Present	Managing Partner/Physician Birmingham Heart Clinic, PC Birmingham, Alabama
2013-2014	Healthcare Editor Trussville Life and Double Oak Mountain Life Birmingham, AL
2013-2014	Clinical Assistant Professor Department of Medicine-Division of Cardiovascular Medicine University of Alabama at Birmingham Birmingham, AL
2010-2011	Preceptor Kansas City University of Medicine and Biosciences Kansas City, MO
2009-2010	Adjunct Professor Pikeville College School of Osteopathic Medicine Pikeville, KY
2004-2005	Associate Editor ACP Medicine Philadelphia, PA
1994-1997	Research and Teaching Assistant Department of Chemical Engineering Auburn, AL
1993-1994	Development Engineer Polymers Division, Ciba-Geigy Corporation McIntosh, AL

**Credentials:**

Medical License	Alabama # 17260
Certification	Board Certified Internal Medicine, 1990 Board Certified Gastroenterology, 1993

**Research Experience:**

The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors

Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the XXX vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early and Advanced Stage Superficial Venous Disease

  
\_\_\_\_\_  
Jason Byron Thompson, MD

11/16/20  
\_\_\_\_\_  
Date

Updated November 2020